Skip to content
Back to browse
LUNG Publication-derived

Alveolar Organoids for Disease Modelling (2015)

Full SOP with Academic or a plan

Source Dye et al., 2015 · University of Michigan Medical School · 10.7554/elife.05098.001

Authors: Briana R Dye, David R Hill, Michael AH Ferguson, Yu-Hwai Tsai, Melinda S Nagy, Rachel Dyal, James M Wells, Christopher N Mayhew, Roy Nattiv, Ophir D Klein, Eric S White, Gail H Deutsch, Jason R Spence Duration: 100 days 7 phases Cell source: Human ESC and Human iPSC

Abstract

This protocol describes the step-wise differentiation of human pluripotent stem cells (hESCs and iPSCs) into lung organoids (HLOs) through manipulation of developmental signaling pathways. HLOs consist of epithelial and mesenchymal compartments organized with structural features similar to native lung, including upper airway-like epithelium with basal and ciliated cells, and alveolar-like domains with bipotent progenitor cells. HLOs are transcriptionally similar to human fetal lung and serve as a model for studying lung development, maturation, and disease.

Cell source
Human ESC and Human iPSC
Application
Developmental study and disease modeling

Protocol overview

11 steps across 7 phases

Phase 1 · hESC/iPSC Maintenance Ongoing prior to differentiation
  1. a Maintain hESCs on Matrigel in mTeSR1 medium
Phase 2 · Differentiation into Definitive Endoderm Days 0-3
  1. a Initiate Activin A treatment
Phase 3 · Anterior Foregut Endoderm Differentiation Days 4-7
  1. a Treat with NOG and SB431542 to generate anterior foregut
Phase 4 · Generation of Ventral Anterior Foregut Spheroids Days 4-10
  1. a Add FGF4 and CHIR99021 to generate 3D spheroids
  2. b Embed spheroids in Matrigel droplets
Phase 5 · HH Pathway Enhancement to Generate Lung Progenitors Days 4-10 (concurrent with spheroid generation)
  1. a Add Smoothened agonist (SAG) during spheroid formation phase
Phase 6 · Lung Organoid Expansion and Maturation Days 10-100+
  1. a Supplement media with FGF10 for organoid expansion
  2. b Optional: Seed organoid spheroids onto acellular human lung matrix
Phase 7 · Optional: Detailed Signaling Pathway Optimization (2D Monolayer Phase) Days 4-12 (in parallel, monolayer cultures only)
  1. a Test FGF2 dose response on foregut endoderm
  2. b Test FGF and HH pathway inhibition
  3. c Test SAG ± SU5402 on foregut monolayer

Full SOP

Full SOPs need an account and a plan

Create an account, then get free Academic access (for verified academics) or choose a plan. Plans include step-by-step procedures, reagent concentrations, QC checklists and batch record templates.

Create an account

Already registered? Log in

Attribution

This SOP was written by Organthis based on the published method in Dye et al., 2015. Once the originating laboratory has confirmed it, the SOP is marked Verified.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence